Breakdown | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 |
---|---|---|---|---|---|
Income Statement | |||||
Total Revenue | 1.13T | 1.16T | 1.13T | 911.43B | 863.38B |
Gross Profit | 479.42B | 504.68B | 485.94B | 392.74B | 374.65B |
EBITDA | -60.74B | 102.63B | 105.59B | 60.35B | 66.32B |
Net Income | -47.85B | 4.52B | -103.15B | -26.12B | -15.21B |
Balance Sheet | |||||
Total Assets | 1.22T | 1.39T | 1.41T | 1.34T | 1.30T |
Cash, Cash Equivalents and Short-Term Investments | 89.90B | 127.13B | 183.06B | 118.64B | 127.03B |
Total Debt | 438.17B | 522.58B | 568.29B | 448.65B | 410.70B |
Total Liabilities | 743.56B | 834.67B | 913.90B | 776.62B | 749.05B |
Stockholders Equity | 463.15B | 539.82B | 487.42B | 549.81B | 539.89B |
Cash Flow | |||||
Free Cash Flow | 25.30B | 38.21B | -27.46B | -23.61B | 37.86B |
Operating Cash Flow | 51.09B | 83.34B | 13.32B | 37.44B | 78.06B |
Investing Cash Flow | 24.65B | -44.53B | -37.50B | -51.00B | -34.33B |
Financing Cash Flow | -110.90B | -96.85B | 84.32B | 2.13B | -13.09B |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
78 Outperform | ¥3.76T | 14.83 | 7.61% | 1.80% | 4.83% | 1.58% | |
71 Outperform | ¥658.51B | 13.17 | 7.32% | 4.03% | 4.50% | 56.65% | |
69 Neutral | ¥755.73B | 17.00 | 4.52% | 2.84% | 7.62% | 8.47% | |
67 Neutral | €617.14B | 16.44 | 9.53% | 2.48% | 6.92% | 16.87% | |
64 Neutral | $10.64B | 16.01 | 5.48% | 2.12% | 2.72% | -24.90% | |
52 Neutral | $240.49B | ― | -16.55% | 0.96% | -7.37% | -653.50% |
Konica Minolta reported a decline in revenue by 8.2% for the three months ending June 30, 2025, compared to the same period last year, yet achieved a significant turnaround in profitability with a 411% increase in business contribution profit and a notable operating profit. This financial performance reflects the company’s strategic shift, including the discontinuation of its Precision Medicine Business, which has streamlined operations and improved profitability, signaling a positive outlook for stakeholders.
The most recent analyst rating on (JP:4902) stock is a Hold with a Yen500.00 price target. To see the full list of analyst forecasts on Konica Minolta stock, see the JP:4902 Stock Forecast page.
Konica Minolta has completed the transfer of shares of its subsidiary, Konica Minolta Marketing Services Holding Company Limited, to adm Group LIMITED. This change, effective June 30, 2025, results in the exclusion of the subsidiary from Konica Minolta’s consolidated financial statements, with minimal impact expected on the company’s financial results for the fiscal year ending March 31, 2026.
The most recent analyst rating on (JP:4902) stock is a Hold with a Yen500.00 price target. To see the full list of analyst forecasts on Konica Minolta stock, see the JP:4902 Stock Forecast page.
Konica Minolta reported its consolidated financial results for the fiscal year ending March 31, 2025, showing a slight increase in revenue but a significant decline in operating profit and overall profitability compared to the previous year. The company has classified its Precision Medicine Business as a discontinued operation, impacting its financial metrics. The results indicate challenges in maintaining profitability, with a notable decrease in total assets and equity, and a negative cash flow from financing activities, which may affect stakeholders’ confidence.
The most recent analyst rating on (JP:4902) stock is a Buy with a Yen750.00 price target. To see the full list of analyst forecasts on Konica Minolta stock, see the JP:4902 Stock Forecast page.